Production Linked Incentive Schemes have Strengthened India’s Pharmaceutical, Bulk Drugs and Medical Devices Manufacturing Ecosystem
The government highlighted the outcomes of three interlinked Production Linked Incentive (PLI) schemes covering bulk drugs (Active Pharmaceutical Ingredients), finished pharmaceuticals, and medical devices, aimed at strengthening India's manufacturing ecosystem.
Under the PLI Scheme for Bulk Drugs, 39 projects for manufacturing 28 identified Active Pharmaceutical Ingredients (APIs) have been commissioned, with actual investment of ₹5,210.74 crore against a committed investment of ₹4,330 crore, as of June 2026.
The three schemes together span the value chain — raw materials/APIs, finished formulations, and medical devices — with the objective of cutting import dependence and building globally competitive manufacturing capacity.
These production-linked incentive schemes are distinct from the separate Scheme for Promotion of Bulk Drug Parks, which funds common infrastructure rather than output-based incentives.
PLI Scheme — Core Design and Sector-Wise Architecture
The Production Linked Incentive (PLI) scheme is an industrial policy instrument launched by the Union Cabinet in November 2020 under the Aatmanirbhar Bharat (self-reliant India) initiative. It offers companies a cash incentive calculated as a percentage of incremental sales/production over a base year, rather than an upfront capital subsidy, and was extended across 14 strategic sectors.
Key Details
- Launched November 2020; total outlay across all 14 sectors: ₹1.97 lakh crore
- Incentive typically ranges 4–6% of incremental sales, varying by sector and scheme
- Implemented through sector-specific nodal ministries (Department of Pharmaceuticals for the pharma-related schemes) with the Department for Promotion of Industry and Internal Trade (DPIIT) coordinating overall implementation
- Payouts are performance-linked and disbursed in arrears after verification, not paid upfront
The pharma, bulk drugs and medical devices PLIs are three of the 14 sector-specific applications of this common design.
PLI Scheme for Bulk Drugs (APIs), 2020
This scheme targets India's historical import dependence on Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs) and drug intermediates — much of which was sourced from a narrow set of countries. It identifies 41 critical products across four "target segments": segments 1 and 2 are fermentation-based products, while segments 3 and 4 are chemical-synthesis-based products.
Key Details
- Approved 2020; total financial outlay ₹6,940 crore; implemented by the Department of Pharmaceuticals
- Targets 41 identified critical APIs/KSMs/intermediates
- As of June 2026: 39 projects covering 28 APIs commissioned; investment of ₹5,210.74 crore against a committed ₹4,330 crore (i.e., actual investment exceeds the original commitment)
This is the specific scheme responsible for the API commissioning and investment figures cited in the news.
PLI Scheme for Pharmaceuticals, 2021
A separate track from the Bulk Drugs scheme, this PLI targets finished, high-value pharmaceutical products rather than raw-material APIs — including complex generics, patented/off-patent drugs, biopharmaceutical products, and orphan drugs — to push Indian manufacturers up the value chain from low-margin generics.
Key Details
- Approved 2021; total financial outlay ₹15,000 crore
- Distinguishes eligible product categories by value/complexity (high-value products get preferential treatment) rather than covering all pharmaceutical products uniformly
- Incentive is production/sales-linked, similar in structure to the Bulk Drugs PLI but for a different product basket
Together with the Bulk Drugs PLI, this scheme completes the upstream (API) to downstream (finished drug) manufacturing chain referenced in the ecosystem framing of the news.
PLI Scheme for Medical Devices
This scheme incentivises domestic manufacturing of medical devices — such as cancer care/radiotherapy equipment, cardiac and renal devices, anaesthetics and implants — where India has historically relied heavily on imports.
Key Details
- Total financial outlay ₹3,420 crore
- Incentive rate: 5% on incremental sales of medical devices manufactured in India
- Production/incentive tenure: FY 2022-23 to FY 2026-27 (five years)
This is the third leg of the "pharmaceutical, bulk drugs and medical devices" ecosystem referenced in the news, targeting the device-manufacturing segment specifically.
Distinguishing PLI Bulk Drugs from the Bulk Drug Parks Scheme
A common point of confusion: the Scheme for Promotion of Bulk Drug Parks is not a PLI scheme. It is an infrastructure-grant scheme that funds common facilities (effluent treatment plants, logistics, testing labs) in designated industrial parks, whereas the PLI Bulk Drugs scheme pays incentives linked to actual incremental production/sales by individual companies.
Key Details
- Notified 2020; total financial outlay ₹3,000 crore
- 'In-principle' approval granted to three states: Himachal Pradesh, Gujarat and Andhra Pradesh
- Funding pattern: 70% of common infrastructure project cost for Gujarat and Andhra Pradesh; 90% for Himachal Pradesh (a hilly state); maximum assistance capped at ₹1,000 crore per park
UPSC frequently tests this distinction — an infrastructure/capex grant scheme (Bulk Drug Parks) versus a production-linked incentive scheme (PLI Bulk Drugs) — both aimed at the same underlying goal of API self-reliance but operating through different fiscal instruments.
- PLI scheme (overall): launched November 2020, 14 sectors, ₹1.97 lakh crore total outlay
- PLI Scheme for Bulk Drugs: ₹6,940 crore outlay; 41 critical products; 39 projects/28 APIs commissioned; investment ₹5,210.74 crore vs ₹4,330 crore committed (as of June 2026)
- PLI Scheme for Pharmaceuticals: ₹15,000 crore outlay; approved 2021
- PLI Scheme for Medical Devices: ₹3,420 crore outlay; 5% incentive on incremental sales; tenure FY2022-23 to FY2026-27
- Scheme for Promotion of Bulk Drug Parks (separate, infrastructure-only): ₹3,000 crore outlay; three states — Himachal Pradesh, Gujarat, Andhra Pradesh; funding 70% (90% for HP) of project cost, capped at ₹1,000 crore per park